Abstracts Archive - Page 296 of 2607 - ACR Meeting Abstracts

Abstract Number: 0589 • ACR Convergence 2024
Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
Laura Coates¹, Iain McInnes², M. Elaine Husni³, Cynthia Vizcaya⁴, Weibin Bao⁵ and Philip Mease⁶, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ³Cleveland Clinic, Cleveland, OH, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…
Abstract Number: 1124 • ACR Convergence 2024
Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
Xiaodi Ruan¹, Michael Williams², Gul Karakoc¹, Elizabeth McNeer¹, Leena Choi¹, Jonathan D. Mosley¹, C. Michael Stein¹ and Vivian K. Kawai¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²VUMC, Nashville, TN
Background/Purpose: Glucocorticoids (GCs) are potent anti-inflammatory drugs that are commonly prescribed, particularly for rheumatic and immunologic conditions. Hyperglycemia is an important adverse effect and occurs…
Abstract Number: 1383 • ACR Convergence 2024
Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Gong cheng¹, yingni Li¹, Yun Li¹, Feng Sun¹, Hongyan Wang¹, Qinqin li², Zhilun Li³, Ru Li⁴ and Zhanguo Li⁵, ¹Peking University People's Hospital, Beijing, China, ²Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, China (People's Republic), ³Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, ⁴Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ⁵People’s Hospital Peking University Health Sciences Centre, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…
Abstract Number: 1647 • ACR Convergence 2024
Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission
Cornelia H. Quaack¹, Esther Röder¹, Hetty M. Wintjes¹, Anneke J. van Steensel-Boon¹, Annemarie G.M.G.J. Mulders², Laura C.J. Kranenburg-van Koppen¹ and radboud J.e.m. Dolhain¹, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Time to conception, known as time to pregnancy (TTP), is prolonged in women diagnosed with RA. High rates of infertility, defined as the inability…
Abstract Number: 1596 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis
Bernhard Hellmich¹, Peter Merkel², David Jayne³, Benjamin Terrier⁴, Florence Roufosse⁵, Parameswaran Nair⁶, Nader Khalidi⁶, David J. Jackson⁷, Shunsuke Furuta⁸, Lena Börjesson Sjö⁹, Sofia Necander⁹, Anat Shavit¹⁰, Claire Walton¹¹ and Michael Wechsler¹², ¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ²University of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁶McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁷Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Trust; School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, ⁸Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹¹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹²National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis, with individual manifestations widely ranging…
Abstract Number: 1628 • ACR Convergence 2024
Tocilizumab for Giant Cell Arteritis in Japan over 2 Years: A Multicenter Retrospective Study
Nobuhiro Oda¹, Sho Fukui², Toshihiro Yamaguchi³, Fumika Nagase⁴, Takanori Ito⁵, Mitsuru Watanabe⁵, Yoichiro Haji⁴, Yasuhiro Suyama⁶, Atsushi Nomura⁷, Eishi Uechi⁸, Masei Suda³, Naoho Takizawa⁴, Ryo Rokutanda⁹ and Hiromichi Tamaki¹⁰, ¹Kameda medical center, Department of Rheumatology, Higashi-cho, Kamogawa, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³Suwa Central Hospital, Department of Rheumatology, Nagano, Japan, ⁴Chubu Rosai Hospital, Department of Rheumatology, Aichi, Japan, ⁵Daido Hospital, Department of Rheumatology, Aichi, Japan, ⁶NTT Medical Center Tokyo, Department of Rheumatology, Tokyo, Japan, ⁷Ushiku Aiwa General Hospital, Department of Rheumatology, Ibaraki, Japan, ⁸Yuai Medical Center, Department of Rheumatology, Okinawa, Japan, ⁹Kameda medical center, Department of Rheumatology, Chiba, Japan, ¹⁰St. Luke’s International Hospital, Immuno-Rheumatology Center, Tokyo, Japan
Background/Purpose: The GiACTA trial, a phase III global trial of tocilizumab (TCZ) for giant cell arteritis (GCA), did not involve Japanese patients, and real-world data…
Abstract Number: 1643 • ACR Convergence 2024
Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts
Helen Jarnagin¹, Dillon Popovich², Rezvan Parvizi³, Rosemary Gedert⁴, Lam C. Tsoi⁵, Rachael Wasikowski⁵, Zhiyun Gong¹, Madeline Morrisson⁶, Laurent Perreard⁷, Fred Kolling IV⁷, Dinesh Khanna⁴, Johann Gudjonsson⁴ and Michael Whitfield³, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, West Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴University of Michigan, Ann Arbor, MI, ⁵Michigan, Dept. of Dermatology, Ann Arbor, MI, ⁶Geisel School of Medicine at Dartmouth College, Hanover, NH, ⁷Geisel School of Medicine, Dartmouth College, Lebanon
Background/Purpose: We generated a vertically integrated dataset on treatment naïve patients with dcSSc (diffuse Systemic Sclerosis) skin that includes bulk RNA-seq, single nuclei multiome, and…
Abstract Number: 1538 • ACR Convergence 2024
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, ¹Rush University, Chicago, IL, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Rheum101, Rockville, MD
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 1607 • ACR Convergence 2024
Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Sebastian Klapa¹, Sabrina Arnold², Antje Müller², Andreas Koch³, Anja Staehle⁴, Wataru Kähler³, Harry Heidecke⁵, Gabriela Riemekasten² and Peter Lamprecht², ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, ⁴University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany
Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
Abstract Number: 1524 • ACR Convergence 2024
Thrombocytopenia and Systemic Lupus Erythematosus: A Meta-analysis of Observational Studies
Alexandre Matar¹ and Omer Pamuk², ¹MetroHealth, Westlake, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Thrombocytopenia is one of the hematological abnormalities that can occur in patients with systemic lupus erythematosus (SLE), and it has been shown to affect…
Abstract Number: 1639 • ACR Convergence 2024
Ultrasound Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Mark Matza¹, Sebastian Unizony² and Minna Kohler³, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Winchester, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Fast-track clinics utilizing ultrasound in the initial evaluation of patients with suspected giant cell arteritis (GCA) have been implemented throughout Europe allowing for rapid…
Abstract Number: 1535 • ACR Convergence 2024
Variations in Tacrolimus Whole Blood Concentrations During Pregnancy and Its Implications for Therapeutic Drug Monitoring: A Systematic Review and Meta-analysis
Reem Farhat¹, Arielle Mendel², Isabelle Malhamé², Ami Grunbaum³, Sasha Bernatsky⁴ and Evelyne Vinet², ¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tacrolimus is a pregnancy-compatible immunosuppressive increasingly used in systemic lupus erythematosus (SLE) pregnancies. Physiological changes throughout pregnancy impact tacrolimus pharmacokinetics, altering the drug’s whole…
Abstract Number: 1641 • ACR Convergence 2024
Orbital MRI as a Promising Approach for the Diagnosis of Giant Cell Arteritis in Case of Anterior Ischemic Optical Neuropathy or Central Retinal Artery Occlusion
Guillaume BRENAC¹, Angélique BERNARD¹, Hélène GREIGERT¹, Brivael LEMOGNE², Andre Ramon³, Sylvain AUDIA¹, Vanessa LEGUY-SEGUIN¹, Jérôme RAZANAMAHERY¹, Louis ARNOULD¹, Catherine CREUZOT-GARCHER¹, Bernard Bonnotte⁴ and Maxime SAMSON¹, ¹Dijon University Hospital, Dijon, France, ²Dijon University Hopital, Dijon, France, ³Dijon University Hospital, Besançon, France, ⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France
Background/Purpose: Vision loss associated with acute anterior ischemic optic neuropathy (AION) or central retinal artery occlusion (CRAO) can reveal giant cell arteritis (GCA). In this…
Abstract Number: 1609 • ACR Convergence 2024
Characteristics of a Cohort of Patients with Interstitial Lung Disease and ANCA Positivity in a University Hospital
Cristina Valero¹, Claudia Valenzuela², Elisa Martínez-Besteiro³, Patricia Quiroga Colina⁴, Arantzazu Alfranca⁵, Esther Vicente-rabaneda⁶, Santos Castañeda⁶ and Rosario García-Vicuña⁷, ¹Hospital de la Princesa, Madrid, Spain, ²ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain, Madrid, Madrid, Spain, ³Pulmonology Service, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Immunology Service, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, Madrid, Madrid, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Madrid, Spain
Background/Purpose: The prevalence of ANCA positivity at diagnosis of interstitial lung disease (ILD) ranges between 4-36% for anti-MPO and 2-4% for anti-PR3. ILD is more…
Abstract Number: 1544 • ACR Convergence 2024
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
wanling wei, ling lei, Cheng Zhao, hanyou mo, zhanrui chen, leting zheng, jing wen, Fang Qin, xiaoling liao, wen zeng and fei dong, The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic)
Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].